Beyond PD-1: Roche Maps Further Checkpoints On Cancer Immune Cycle
Roche gave updates on its immunotherapy research at ASCO, setting the stage for an ambitious slate of combination trials with the company's PD-L1 inhibitor atezolizumab.
You may also be interested in...
In an audio interview from the recent ASCO-SITC meeting, Chen weighs in on comparisons of PD-1 and PD-L1 inhibitors, the IDO failures, biomarkers and his new work at the private biotech IGM Biosciences.
Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.